Israpafant is a potent, selective, and long-acting platelet-activating factor (PAF) receptor antagonist; it inhibits PAF-induced platelet aggregation in humans and rabbits (IC50 = 0.84 nM and 3.84 nM, respectively); it suppresses allergic skin reactions in mice, including eosinophil infiltration, cytokine production, edema, and erythema; it stimulates extracellular Ca2+ influx and intracellular Ca2+ release in prostate cancer cells.